PRMT5 and mantle cell lymphoma: A SAM-uncompetitive pharmacological inhibitor of PRMT5 (EPZ015666/GSK3326595) was shown to be an effective anti-proliferative agent in mantle cell lymphoma (MCL) models with overexpression of PRMT5 (83).